Pemetrexed (Alimta)
Malignant pleural neoplasm with both differentiation of epithelioid mesothelioma and squamous-cell carcinoma, a rare phenomena
Diagnostic Cytopathology 2020 December 21 [Link] Ashley Re, David Shersher, Ashleigh Allen, Roland Schwarting, Shuyue Ren Abstract Malignant mesothelioma, a neoplasm arising within the serosal surfaces, has been linked closely to asbestos exposure. We present a case of 72-year-old male with a 27 year work-related history of asbestos exposure who presented with dyspnea. Chest computed…
Read MoreThe Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis
Frontiers in Oncology 2020 November 13 [Link] Olivia Lauk, Karina Bruestle, Thomas Neuer, Bianca Battilana, Thi Dan Linh Nguyen, Thomas Frauenfelder, Rolf Stahel, Walter Weder, Alessandra Curioni-Fontecedro, Isabelle Opitz Abstract Objectives: Adding bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF), to platinum-based chemotherapy/pemetrexed in 1st line treatment of advanced malignant pleural mesothelioma (MPM), significantly improved overall…
Read MoreOncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716
Lung Cancer 2020 October 20 [Link] Sarah J Danson, Joe Conner, John G Edwards, Kevin G Blyth, Patricia M Fisher, Munitta Muthana, Abdulazeez Salawu, Fiona Taylor, Elizabeth Hodgkinson, Patrick Joyce, Jennifer Roman, Kathleen Simpson, Alexander Graham, Kirsty Learmonth, Penella J Woll Abstract Objectives: Malignant Pleural Mesothelioma (MPM) remains a major oncological challenge with limited therapeutic…
Read MoreDurvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
The Lancet Oncology 2020 September [Link] Anna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, Chris Brown, Brett Gm Hughes, Deme J Karikios, Thomas John, Steven C-H Kao, Connull Leslie, Alistair M Cook, Nick Pavlakis, Karen Briscoe, Kenneth J O’Byrne, Christos S Karapetis, Wei-Sen Lam, Ailsa Langford, Sonia Yip, Martin R Stockler Abstract Background: There is…
Read MoreRandomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901
Clinical Lung Cancer 2020 July 3 [Link] Arkadiusz Z Dudek, Xiaofei Wang, Lin Gu, Stephanie Duong, Thomas E Stinchcombe, Robert Kratzke, Hossein Borghaei, Everett E Vokes, Hedy L Kindler Abstract Background: The role of maintenance therapy for malignant pleural mesothelioma (MPM) is unknown. We performed a randomized phase II trial to determine if continuation of…
Read MoreGanetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial
Clinical Cancer Research 2020 July 15 [Link] Dean A Fennell, Sarah Danson, Penella J Woll, Martin Forster, Denis Talbot, Jennifer Child, Laura Farrelly, Annabel Sharkey, Sara Busacca, Yenting Ngai, Allan Hackshaw, Graham M Wheeler Abstract Purpose: Ganetespib, a highly potent, small-molecule Heatshock protein 90 inhibitor, has potential efficacy in malignant pleural mesothelioma (MPM) via activity…
Read MoreCisplatin Plus Pemetrexed Therapy and Subsequent Immune Checkpoint Inhibitor Administration for Malignant Peritoneal Mesothelioma Without Pleural Lesions: Case Report
Medicine 2020 May 29 [Link] Hiroaki Ikushima, Toshio Sakatani, Sayaka Ohara, Hideyuki Takeshima, Hajime Horiuchi, Teppei Morikawa, Kazuhiro Usui Abstract Rationale: Malignant peritoneal mesothelioma is a rare tumor with a poor prognosis and has no recommended therapy after first-line pemetrexed and platinum-based chemotherapy. Moreover, effects of immune checkpoint inhibitors on peritoneal mesothelioma remains to be…
Read MoreImmunotherapy in Malignant Pleural Mesothelioma.
Frontiers in Oncology 2020 February 21 [Link] de Gooijer CJ, Borm FJ, Scherpereel A, Baas P Abstract The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most…
Read MoreHow I treat malignant pleural mesothelioma.
ESMO Open 2020 March [Link] Viscardi G, Di Liello R, Morgillo F Abstract Malignant pleural mesothelioma is a rare and aggressive malignancy mostly associated with occupational asbestos exposure. Prognosis is poor and only highly selected patients may benefit from aggressive surgical management, also as part of a multimodal approach. In advanced disease, the combination of…
Read MoreA phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Lung Cancer 2020 February 12 [Link] Zucali PA, Perrino M, De Vincenzo F, Giordano L, Cordua N, D’Antonio F, Santoro A Abstract OBJECTIVES: Second-line chemotherapy is not a standard of care in patients with malignant pleural mesothelioma (MPM) that progresses after first-line treatment with cisplatin and pemetrexed. In pre-clinical models, the combination of gemcitabine (GEM)…
Read More